Skip to Content

Curaleaf Holdings Inc CURLF

Morningstar Rating
$5.00 −0.14 (2.72%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Curaleaf's Long-Term Potential Shrouded by Near-Term Uncertainty Around Legalization Pace

Curaleaf cultivates and sells cannabis in the U.S. with a presence in 18 states. Vertically integrated, Curaleaf produces through 21 cultivation sites and sells directly through 146 dispensaries and wholesale to other dispensaries. Compared with other multistate operators, Curaleaf has generally employed a more aggressive growth strategy, which hasn't always paid off, leading to exits and sales.

Price vs Fair Value

CURLF is trading at a 62% discount.
Price
$5.00
Fair Value
$39.00
Uncertainty
Very High
1-Star Price
$35.15
5-Star Price
$2.10
Economic Moat
Vvxqm
Capital Allocation
Jspkxsn

Bulls Say, Bears Say

Bulls

Curaleaf’s acquisition of EMMAC Life Sciences gives it cheap Portugal production and a base to build its European business around.

Bears

Sales growth for legal sellers like Curaleaf are challenged by the lack of taxes in the illicit market.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CURLF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.14
Day Range
$4.965.25
52-Week Range
$2.195.80
Bid/Ask
$4.98 / $5.11
Market Cap
$3.67 Bil
Volume/Avg
286,755 / 928,477

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.67
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 18 states. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
5,931

Competitors

Valuation

Metric
CURLF
CGC
TLRY
Price/Earnings (Normalized)
Price/Book Value
3.320.710.39
Price/Sales
2.671.041.75
Price/Cash Flow
Price/Earnings
CURLF
CGC
TLRY

Financial Strength

Metric
CURLF
CGC
TLRY
Quick Ratio
0.291.130.89
Current Ratio
0.871.791.63
Interest Coverage
−2.47−9.27−24.18
Quick Ratio
CURLF
CGC
TLRY

Profitability

Metric
CURLF
CGC
TLRY
Return on Assets (Normalized)
−6.81%−23.44%−1.87%
Return on Equity (Normalized)
−17.81%−57.88%−2.39%
Return on Invested Capital (Normalized)
−6.76%−20.86%−1.58%
Return on Assets
CURLF
CGC
TLRY
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ALpwj$91.1 Bil
MKKGY
Merck KGaA ADRDkhdbjz$74.5 Bil
HLN
Haleon PLC ADRGmp$37.7 Bil
VTRS
Viatris IncZzcr$15.9 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRJfps$15.1 Bil
RDY
Dr Reddy's Laboratories Ltd ADRMfgw$13.0 Bil
CTLT
Catalent IncBkvwdg$10.5 Bil
PRGO
Perrigo Co PLCFsgw$3.7 Bil
PBH
Prestige Consumer Healthcare IncKcrksm$3.5 Bil

Sponsor Center